Biophytis (BPTSY) Competitors

$0.40 0.00 (0.00%)
As of 11/9/2026

BPTSY vs. ADXN, TRAW, RDHL, SILO, and EOCN

Should you buy Biophytis stock or one of its competitors? Biophytis's main competitors and comparable companies include Addex Therapeutics (ADXN), Traws Pharma (TRAW), Redhill Biopharma (RDHL), Silo Pharma (SILO), and Galmed Pharmaceuticals (EOCN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biophytis compare to Addex Therapeutics?

Biophytis (NASDAQ:BPTSY) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Biophytis has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Addex Therapeutics has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
Addex Therapeutics$210K19.91-$8.12M-$5.94N/A

In the previous week, Addex Therapeutics had 1 more articles in the media than Biophytis. MarketBeat recorded 2 mentions for Addex Therapeutics and 1 mentions for Biophytis. Addex Therapeutics' average media sentiment score of 0.32 beat Biophytis' score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biophytis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Addex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Biophytis' return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Addex Therapeutics N/A -174.44%-126.47%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Addex Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.1% of Biophytis shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 3.7% of Biophytis shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Addex Therapeutics beats Biophytis on 7 of the 10 factors compared between the two stocks.

How does Biophytis compare to Traws Pharma?

Biophytis (NASDAQ:BPTSY) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 3.7% of Biophytis shares are owned by company insiders. Comparatively, 8.7% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Traws Pharma has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
Traws Pharma$2.79M1.27$9.17M-$1.58N/A

Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 334.78%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than Biophytis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Traws Pharma
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, Traws Pharma had 10 more articles in the media than Biophytis. MarketBeat recorded 11 mentions for Traws Pharma and 1 mentions for Biophytis. Traws Pharma's average media sentiment score of 0.92 beat Biophytis' score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biophytis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Traws Pharma
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biophytis' return on equity of 0.00% beat Traws Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Traws Pharma N/A -23,868.92%-182.69%

Biophytis has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

Summary

Traws Pharma beats Biophytis on 8 of the 11 factors compared between the two stocks.

How does Biophytis compare to Redhill Biopharma?

Biophytis (NASDAQ:BPTSY) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Biophytis has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.93, meaning that its share price is 393% more volatile than the broader market.

In the previous week, Biophytis and Biophytis both had 1 articles in the media. Biophytis' average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biophytis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Redhill Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Net Margins Return on Equity Return on Assets
BiophytisN/A N/A N/A
Redhill Biopharma N/A N/A N/A

0.1% of Biophytis shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 3.7% of Biophytis shares are owned by company insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Redhill Biopharma has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiophytisN/AN/A-$18.43MN/AN/A
Redhill Biopharma$290K9.91-$430KN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Redhill Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Redhill Biopharma beats Biophytis on 6 of the 6 factors compared between the two stocks.

How does Biophytis compare to Silo Pharma?

Silo Pharma (NASDAQ:SILO) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Silo Pharma had 1 more articles in the media than Biophytis. MarketBeat recorded 2 mentions for Silo Pharma and 1 mentions for Biophytis. Silo Pharma's average media sentiment score of 1.50 beat Biophytis' score of 0.00 indicating that Silo Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silo Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Biophytis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silo Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Silo Pharma has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market.

5.6% of Silo Pharma shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 3.6% of Silo Pharma shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Silo Pharma has higher revenue and earnings than Biophytis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silo Pharma$70K58.01-$4.23M-$2.77N/A
BiophytisN/AN/A-$18.43MN/AN/A

Biophytis has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Biophytis' return on equity of 0.00% beat Silo Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Silo Pharma-6,726.39% -58.79% -50.68%
Biophytis N/A N/A N/A

Summary

Silo Pharma beats Biophytis on 6 of the 11 factors compared between the two stocks.

How does Biophytis compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:EOCN) and Biophytis (NASDAQ:BPTSY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galmed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Biophytis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galmed PharmaceuticalsN/AN/A-$10.31M-$15.18N/A
BiophytisN/AN/A-$18.43MN/AN/A

Biophytis' return on equity of 0.00% beat Galmed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Galmed PharmaceuticalsN/A -73.68% -60.88%
Biophytis N/A N/A N/A

Galmed Pharmaceuticals has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Biophytis has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market.

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Biophytis. MarketBeat recorded 2 mentions for Galmed Pharmaceuticals and 1 mentions for Biophytis. Galmed Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galmed Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biophytis
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Galmed Pharmaceuticals beats Biophytis on 5 of the 8 factors compared between the two stocks.

Get Biophytis News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPTSY vs. The Competition

MetricBiophytisPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$938K$13.35B$7.59B$11.70B
Dividend YieldN/A2.60%2.48%4.65%
P/E RatioN/A26.9031.9926.76
Price / SalesN/A7.098.405.53
Price / CashN/A15.5320.7221.66
Price / Book-0.025.304.423.65
Net Income-$18.43M$2.87B$3.51B$394.00M
7 Day PerformanceN/A-5.14%-5.44%-5.74%
1 Month PerformanceN/A-7.77%-8.62%-9.54%
1 Year PerformanceN/A-6.74%-1.31%-6.71%

Biophytis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPTSY
Biophytis
N/A$0.40
flat
N/AN/A$938KN/AN/A30
ADXN
Addex Therapeutics
0.5896 of 5 stars
$2.84
-1.7%
N/A-60.5%$3.56M$29.97KN/A3
TRAW
Traws Pharma
2.2042 of 5 stars
$0.25
+11.1%
$1.00
+300.0%
-89.1%$3.46M$2.79MN/A7
RDHL
Redhill Biopharma
0.4893 of 5 stars
$0.37
-2.4%
N/A-68.9%$3.33M$290KN/A210
SILO
Silo Pharma
1.2697 of 5 stars
$1.84
+2.9%
N/A-68.3%$2.84M$70KN/A3

Related Companies and Tools


This page (NASDAQ:BPTSY) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners